糖尿病性胃不全麻痺治療市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別（グレード2、グレード3）、薬剤クラス別、投与経路別、流通チャネル別、地域別、競合別セグメント、2020-2030年

糖尿病性胃不全麻痺治療の世界市場規模は2024年に28億9,000万米ドルとなり、2030年までCAGR 3.23％で安定した成長が予測されています。

同市場は、糖尿病の合併症である胃排出遅延を特徴とする糖尿病性胃不全麻痺の管理に対応しています。糖尿病患者が世界的に急増するにつれ、胃不全麻痺の有病率も増加し、効果的な治療オプションに対する需要が高まっています。Frontiers誌の2025年の研究によると、胃腸症状は糖尿病患者の5％から12％に影響を及ぼしており、診断・治療ソリューションの改善の必要性が強調されています。同市場は医薬品、食事療法、医療機器にまたがっており、主な製品には消化促進剤、制吐剤、栄養補助ツールなどがあります。これらの治療法は、吐き気、嘔吐、腹痛、消化不良などの症状を緩和し、最終的に患者の生活の質を高めることを目的としています。患者中心のケアと革新的な治療法が重視されるようになったことで、この進化するヘルスケアの展望は形を変え続けています。

市場促進要因

糖尿病の有病率の上昇

主な市場課題

限られた治療オプション

主要市場動向

個別化医療

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の糖尿病性胃不全麻痺治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（グレード2（代償性胃不全麻痺）、グレード3（胃不全麻痺））
  • 薬剤クラス別（消化管運動促進剤、制吐剤、抗ヒスタミン剤、その他）
  • 投与経路（経口、非経口、経鼻）
  • 流通チャネル別（病院薬局、小売薬局、オンライン薬局）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • タイプ別
  • 薬剤クラス別
  • 投与経路別
  • 流通チャネル別
  • 地域別

第5章 アジア太平洋地域の糖尿病性胃不全麻痺治療市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 薬剤クラス別
  • 投与経路別
  • 流通チャネル別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の糖尿病性胃不全麻痺治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の糖尿病性胃不全麻痺治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の糖尿病性胃不全麻痺治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの糖尿病性胃不全麻痺治療市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の糖尿病性胃不全麻痺治療： SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• ANI Pharmaceuticals, Inc.
• Evoke Pharma
• Janssen Pharmaceutica N.V
• Teva Pharmaceuticals Inc.
• Pfizer Inc.
• Salix Pharmaceuticals, Inc.
• Allergan
• Novartis AG
• SCHWITZ BIOTECH
• Wellona Pharma

第15章 戦略的提言

第16章 調査会社について・免責事項

The Global Diabetic Gastroparesis Treatment Market was valued at USD 2.89 billion in 2024 and is projected to witness steady growth at a CAGR of 3.23% through 2030. This market addresses the management of diabetic gastroparesis, a complication of diabetes marked by delayed stomach emptying. As diabetes cases surge globally, so too does the prevalence of gastroparesis, intensifying the demand for effective treatment options. According to a 2025 study in Frontiers, gastrointestinal symptoms affect 5% to 12% of diabetic individuals, highlighting the need for improved diagnostic and treatment solutions. The market spans pharmaceuticals, dietary modifications, and medical devices, with key products including prokinetic agents, antiemetics, and nutritional support tools. These treatment modalities aim to alleviate symptoms like nausea, vomiting, abdominal pain, and indigestion, ultimately enhancing patients' quality of life. The growing emphasis on patient-centric care and innovative therapies continues to reshape this evolving healthcare landscape.

Key Market Drivers

Rising Prevalence of Diabetes

A significant driver of the Global Diabetic Gastroparesis Treatment Market is the escalating prevalence of diabetes worldwide. Both type 1 and type 2 diabetes have reached alarming levels, with WHO data showing an increase in global diabetes cases from 200 million in 1990 to 830 million in 2022. Among these individuals, approximately 20% experience diabetic gastroparesis due to nerve damage affecting stomach motility. The link between chronic hyperglycemia and gastrointestinal complications means that as diabetes becomes more widespread, so does the incidence of gastroparesis. Notably, in 2022, 14% of adults aged 18+ had diabetes, and over half of diabetic adults aged 30+ remained untreated-particularly in low- and middle-income countries. This growing diabetic population continues to fuel demand for effective treatment options that address gastroparesis symptoms and prevent further complications, positioning this segment as a critical focus within global healthcare.

Key Market Challenges

Limited Treatment Options

Despite progress in managing diabetic gastroparesis, the market still struggles with limited treatment options. The primary drugs used-prokinetic agents and antiemetics-offer only partial relief and are not effective for all patients. This narrow pharmaceutical toolkit leaves many individuals without adequate solutions for persistent symptoms like nausea, bloating, and abdominal pain. The lack of diverse and universally effective medications restricts clinicians' ability to personalize treatment and achieve consistent patient outcomes. Moreover, when standard therapies fail, patients often endure ongoing discomfort, leading to diminished quality of life. Healthcare providers also face difficulty managing a condition that lacks sufficient therapeutic diversity. Addressing this challenge requires greater investment in R&D to develop novel drugs, improve existing formulations, and introduce more targeted treatment approaches capable of catering to a wider range of patient responses.

Key Market Trends

Personalized Medicine

Personalized medicine is gaining momentum in the Global Diabetic Gastroparesis Treatment Market as a transformative trend focused on tailoring treatments to individual patient needs. Since diabetic gastroparesis presents differently across patients, personalization enables more precise and effective symptom management. By factoring in each patient's medical history, symptom severity, and therapeutic response, healthcare providers can optimize treatment strategies-choosing between drug classes like prokinetic agents, antiemetics, or alternative therapies as appropriate. This customized approach improves efficacy, reduces side effects, and enhances patient satisfaction. The rise of personalized medicine underscores a shift toward targeted care, where data-driven decisions and individualized protocols support better health outcomes and address the variability inherent in diabetic gastroparesis cases.

Key Market Players

• ANI Pharmaceuticals, Inc.
• Evoke Pharma
• Janssen Pharmaceutica N.V
• Teva Pharmaceuticals Inc.
• Pfizer Inc.
• Salix Pharmaceuticals, Inc.
• Allergan
• Novartis AG
• SCHWITZ BIOTECH
• Wellona Pharma

Report Scope:

In this report, the Global Diabetic Gastroparesis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diabetic Gastroparesis Treatment Market, By Type:

• Grade 2 (Compensated Gastroparesis)
• Grade 3 (Gastric Failure)

Diabetic Gastroparesis Treatment Market, By Route of Administration:

• Oral
• Parenteral
• Nasal

Diabetic Gastroparesis Treatment Market, By Drug Class:

• Gastroprokinetic Agents
• Antiemetic Agents
• Antihistamines
• Others

Diabetic Gastroparesis Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Diabetic Gastroparesis Treatment Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diabetic Gastroparesis Treatment Market.

Available Customizations:

Global Diabetic Gastroparesis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Diabetic Gastroparesis Treatment Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Grade 2(Compensated Gastroparesis), Grade 3(Gastric Failure))
  • 4.2.2. By Drug Class (Gastroprokinetic Agents, Antiemetic Agents, Antihistamines, Others)
  • 4.2.3. By Route of Administration (Oral, Parenteral, Nasal)
  • 4.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
  • 4.2.5. By Region
  • 4.2.6. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Drug Class
  • 4.3.3. By Route of Administration
  • 4.3.4. By Distribution Channel
  • 4.3.5. By Region

5. Asia Pacific Diabetic Gastroparesis Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Drug Class
  • 5.2.3. By Route of Administration
  • 5.2.4. By Distribution Channel
  • 5.2.5. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Diabetic Gastroparesis Treatment Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Drug Class
      • 5.3.1.2.3. By Route of Administration
      • 5.3.1.2.4. By Distribution Channel
  • 5.3.2. India Diabetic Gastroparesis Treatment Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Drug Class
      • 5.3.2.2.3. By Route of Administration
      • 5.3.2.2.4. By Distribution Channel
  • 5.3.3. Australia Diabetic Gastroparesis Treatment Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Drug Class
      • 5.3.3.2.3. By Route of Administration
      • 5.3.3.2.4. By Distribution Channel
  • 5.3.4. Japan Diabetic Gastroparesis Treatment Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Drug Class
      • 5.3.4.2.3. By Route of Administration
      • 5.3.4.2.4. By Distribution Channel
  • 5.3.5. South Korea Diabetic Gastroparesis Treatment Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Drug Class
      • 5.3.5.2.3. By Route of Administration
      • 5.3.5.2.4. By Distribution Channel

6. Europe Diabetic Gastroparesis Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Diabetic Gastroparesis Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Class
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Germany Diabetic Gastroparesis Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Class
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Spain Diabetic Gastroparesis Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Class
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel
  • 6.3.4. Italy Diabetic Gastroparesis Treatment Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Drug Class
      • 6.3.4.2.3. By Route of Administration
      • 6.3.4.2.4. By Distribution Channel
  • 6.3.5. United Kingdom Diabetic Gastroparesis Treatment Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Drug Class
      • 6.3.5.2.3. By Route of Administration
      • 6.3.5.2.4. By Distribution Channel

7. North America Diabetic Gastroparesis Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Type
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Route of Administration
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Diabetic Gastroparesis Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Class
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. Mexico Diabetic Gastroparesis Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Class
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. Canada Diabetic Gastroparesis Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Class
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel

8. South America Diabetic Gastroparesis Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Type
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Route of Administration
  • 8.2.5. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Diabetic Gastroparesis Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Class
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. Argentina Diabetic Gastroparesis Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Class
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Colombia Diabetic Gastroparesis Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Class
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel

9. Middle East and Africa Diabetic Gastroparesis Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Diabetic Gastroparesis Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Class
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. Saudi Arabia Diabetic Gastroparesis Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. UAE Diabetic Gastroparesis Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Class
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel
  • 9.3.4. Egypt Diabetic Gastroparesis Treatment Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Type
      • 9.3.4.2.2. By Drug Class
      • 9.3.4.2.3. By Route of Administration
      • 9.3.4.2.4. By Distribution Channel

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Diabetic Gastroparesis Treatment: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. ANI Pharmaceuticals, Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. Evoke Pharma
• 14.3. Janssen Pharmaceutica N.V
• 14.4. Teva Pharmaceuticals Inc.
• 14.5. Pfizer Inc.
• 14.6. Salix Pharmaceuticals, Inc.
• 14.7. Allergan
• 14.8. Novartis AG
• 14.9. SCHWITZ BIOTECH
• 14.10. Wellona Pharma

15. Strategic Recommendations

16. About Us & Disclaimer